Clinical Trial Update: Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety of TTAC-0001 (Tanibirumab) in patients with recurrent glioblastoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• TTAC-0001 (Tanibirumab)

Snippet

Sponsor: PharmAbcine | Conditions: Recurrent Glioblastoma | Phase 2 | Status: COMPLETED